Get the Stockscreener App
8.61
1.06%
0.09
After Hours:
8.46
-0.15
-1.74%
Vir Biotechnology Inc stock is traded at $8.61, with a volume of 1.18M.
It is up +1.06% in the last 24 hours and down -8.40% over the past month.
Vir Biotechnology Inc is a clinical-stage biopharmaceutical company focused on powering the immune system by discovering and developing medicines for serious infectious diseases and cancer. The company uses its capabilities in antibody discovery and engineering, coupled with its proprietary AI engine dAIsY system, and the PRO-XTEN masking platform, to quickly and effectively discover and optimize potential new medicines. Its clinical development pipeline consists of investigational therapies like Tobevibart + elebsiran targeting the hepatitis delta virus (HDV), preclinical antibody candidates targeting HIV, and VIR-5500, VIR-5818, VIR-5525, and 7 PRO-XTEN programs targeting multiple solid tumors. Currently, the company generates revenue mainly by issuing license rights and through grants.
See More
Previous Close:
$8.52
Open:
$8.68
24h Volume:
1.18M
Relative Volume:
0.64
Market Cap:
$1.45B
Revenue:
$68.56M
Net Income/Loss:
$-437.99M
P/E Ratio:
-2.7213
EPS:
-3.1639
Net Cash Flow:
$-396.61M
1W Performance:
-0.46%
1M Performance:
-8.40%
6M Performance:
+28.70%
1Y Performance:
+64.94%
1-Day Range:
$8.52
$8.86
1-Week Range:
$8.16
$8.92
52-Week Range:
$4.155
$11.66
Vir Biotechnology Inc Stock (VIR) Company Profile
Name
Vir Biotechnology Inc
Sector
Industry
Phone
415-906-4324
Address
1800 OWENS STREET, SAN FRANCISCO, CA
Compare VIR vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VIR
Vir Biotechnology Inc
|
8.61 | 1.44B | 68.56M | -437.99M | -396.61M | -3.1639 |
VRTX
Vertex Pharmaceuticals Inc
|
444.93 | 112.95B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
612.14 | 64.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
893.52 | 55.90B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.85 | 38.64B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
153.87 | 31.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Vir Biotechnology Inc Stock (VIR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-24-26 | Upgrade | Raymond James | Outperform → Strong Buy |
| Sep-03-25 | Initiated | Evercore ISI | Outperform |
| Aug-27-25 | Upgrade | BofA Securities | Neutral → Buy |
| Jan-29-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Sep-08-23 | Downgrade | BofA Securities | Buy → Neutral |
| Mar-06-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Feb-21-23 | Upgrade | Goldman | Neutral → Buy |
| Jan-27-23 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Sep-14-22 | Initiated | SVB Leerink | Outperform |
| Sep-09-22 | Initiated | Morgan Stanley | Underweight |
| Mar-03-22 | Upgrade | Robert W. Baird | Underperform → Neutral |
| Dec-21-21 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Oct-25-21 | Upgrade | JP Morgan | Underweight → Neutral |
| Sep-22-21 | Downgrade | Goldman | Buy → Neutral |
| Jun-04-21 | Resumed | Robert W. Baird | Neutral |
| Jan-27-21 | Downgrade | JP Morgan | Neutral → Underweight |
| Jan-20-21 | Reiterated | H.C. Wainwright | Buy |
| Oct-05-20 | Initiated | BofA Securities | Buy |
| Sep-14-20 | Upgrade | Goldman | Neutral → Buy |
| Sep-11-20 | Upgrade | JP Morgan | Underweight → Neutral |
| Aug-20-20 | Initiated | Needham | Buy |
| Mar-19-20 | Downgrade | JP Morgan | Neutral → Underweight |
| Mar-13-20 | Downgrade | Goldman | Buy → Neutral |
| Feb-27-20 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Feb-04-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Nov-14-19 | Initiated | Robert W. Baird | Neutral |
| Nov-05-19 | Initiated | Barclays | Overweight |
| Nov-05-19 | Initiated | Cowen | Outperform |
| Nov-05-19 | Initiated | Goldman | Buy |
| Nov-05-19 | Initiated | JP Morgan | Overweight |
View All
Vir Biotechnology Inc Stock (VIR) Latest News
VIR Maintained by Morgan Stanley -- Price Target Raised to $27 - GuruFocus
Morgan Stanley Raises Vir Biotechnology (NASDAQ:VIR) Price Target to $27.00 - MarketBeat
Vir Biotechnology, Inc. Stock 12‑Month Price Target Raised to $21.56, Implies 161% Upside - TradingView
Vir Biotechnology Announces Appointment of Timothy Coughlin to its Board of Directors - BioSpace
Vir Biotechnology (VIR) director awarded RSUs and stock options in new grants - Stock Titan
Vir Biotechnology (VIR) director Coughlin reports zero share ownership - Stock Titan
Vir Biotechnology Adds Timothy Coughlin to Board, Audit Chair - TipRanks
Vir Biotechnology appoints Timothy Coughlin to board By Investing.com - Investing.com Australia
Vir Biotechnology (VIR) appoints Timothy Coughlin as director and Audit Committee chair - Stock Titan
Vir Biotechnology appoints Timothy Coughlin to board - Investing.com
WINTON GROUP Ltd Buys 131,555 Shares of Vir Biotechnology, Inc. $VIR - MarketBeat
Why Did Vir Biotechnology Stock Surge 60% After-Hours Today? - Stocktwits
Vir Biotechnology: Analyzing the Bullish Thesis on VIR-5500 and mCRPC OpportunityAnalyst Coverage Count - newsline.com
Vir Biotechnology Stock Has Nearly Doubled in a Year. One Major Holder Just Trimmed $17 Million - AOL.com
VIR Stock Surges 60% Pre-Market Today – Analysts Cheer Strong Cancer Data, Astellas Partnership - Stocktwits
VIR News | VIR BIOTECHNOLOGY INC (NASDAQ:VIR) - ChartMill
Is Vir Biotechnology, Inc. (VIR) A Good Stock To Buy Now? - Insider Monkey
Earnings call transcript: Vir Biotech reports larger-than-expected Q1 2026 loss - Investing.com
Vir Biotech Q1 2026 presentation: $2.2B partnerships fuel oncology pivot - Investing.com
VIR Maintained by Leerink Partners -- Price Target Raised to $21 - GuruFocus
Vir Biotechnology (NASDAQ:VIR) Price Target Raised to $21.00 - MarketBeat
Insider Sell: Brent Sabatini Sells Shares of Vir Biotechnology I - GuruFocus
Insider Sell: Janet Napolitano Sells 3,200 Shares of Vir Biotech - GuruFocus
Vir Biotechnology director Janet Napolitano sells $30,239 in stock - Investing.com UK
Vir Biotechnology director Janet Napolitano sells $30,239 in stock By Investing.com - Investing.com India
Vir Biotechnology (VIR) director Napolitano sells 3,200 shares under 10b5-1 plan - Stock Titan
Vir Biotechnology (VIR) SVP sells 379 shares in pre-planned trade - Stock Titan
VIR (NASDAQ: VIR) Form 144 lists 379 ESPP shares; insider sold 7,711 - Stock Titan
[144] Vir Biotechnology, Inc. SEC Filing - Stock Titan
Barclays Maintains Vir Biotechnology(VIR.US) With Buy Rating, Maintains Target Price $30 - Moomoo
Vir Biotechnology, Inc. (VIR) Presents at EASL Congress 2026Slideshow (NASDAQ:VIR) 2026-05-30 - Seeking Alpha
Vir Biotechnology (VIR) director receives RSU and stock option grants - Stock Titan
Vir Biotechnology (VIR) director granted 8,000 RSUs and 16,000 options - Stock Titan
Vir Biotechnology (VIR) director granted RSUs and 16,000-share stock option - Stock Titan
Vir Biotechnology (VIR) director receives 8,000 RSUs and 16,000 stock options - Stock Titan
Vir Biotechnology (VIR) director awarded 8,000 RSUs and 16,000-share stock option - Stock Titan
Vir Biotechnology (VIR) director granted RSUs and 16,000-share option - Stock Titan
Vir Biotechnology, Inc. 8-K Filing Details for May 25, 2026: Company Information, NASDAQ Listing, and Executive Certification - Minichart
Vir Biotechnology, Inc. Announces Changes in Board and Audit Committee, Effective May 26, 2026 - marketscreener.com
Analysts Offer Insights on Healthcare Companies: AnaptysBio (ANAB), GeoVax Labs (GOVX) and Vir Biotechnology (VIR) - The Globe and Mail
Vir Biotechnology (Nasdaq: VIR) reports director exit and 2026 vote outcomes - Stock Titan
Vir Biotechnology, Inc. (NASDAQ:VIR) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Why a Biotech Fund Opened a New $6 Million Position in Vir Amid a 99% Stock Rally - AOL.com
UBS Group AG Purchases 203,203 Shares of Vir Biotechnology, Inc. $VIR - MarketBeat
Gilead wins hepatitis D drug approval as two Bay Area rivals line up their drugs - The Business Journals
How Marianne De Backer saved Vir after flu drug failure - The Business Journals
Vir Biotechnology Inc Stock (VIR) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.04%
0.76%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):